Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey

Aliment Pharmacol Ther. 2006 Mar 1;23(5):655-68. doi: 10.1111/j.1365-2036.2006.02810.x.

Abstract

Aim: To assess primary care physician perceptions of non-steroidal anti-inflammatory drug (NSAID) and aspirin-associated toxicity.

Methods: A group of gastroenterologists and internal medicine physicians created a survey, which was administered via the Internet to a large number of primary care physicians from across the US.

Results: One thousand primary care physicians participated. Almost one-third of primary care physicians recommended 325 mg rather than 81 mg of aspirin/day for cardioprotection. Fifty-nine percent thought enteric-coated or buffered aspirin reduced the risk of upper gastrointestinal (GI) bleeding. Seventy-six percent believed that Helicobacter pylori infection increased the risk of NSAID ulcers but fewer than 25% tested NSAID users for this infection. More than two-thirds were aware that aspirin co-therapy decreased the GI safety benefits of the cyclo-oxygenase 2 selective NSAIDs. However, 84% felt that aspirin with a cyclo-oxygenase 2 selective NSAID was safer than aspirin with a non-selective NSAID. When presented a patient at high risk for NSAID-related GI toxicity, almost 50% of primary care physicians recommended a proton pump inhibitor and cyclo-oxygenase 2 selective NSAID.

Conclusions: This survey has identified areas of misinformation regarding the risk-benefit of NSAIDs and aspirin and the utilization of gastroprotective strategies. Further education on NSAIDs for primary care physicians is warranted.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Aspirin / adverse effects*
  • Aspirin / therapeutic use
  • Attitude of Health Personnel
  • Cardiotonic Agents / adverse effects
  • Cardiotonic Agents / therapeutic use
  • Cyclooxygenase 2 Inhibitors / adverse effects
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Female
  • Gastrointestinal Hemorrhage / complications
  • Health Care Surveys
  • Helicobacter Infections / complications
  • Helicobacter pylori
  • Humans
  • Male
  • Middle Aged
  • Peptic Ulcer / chemically induced
  • Peptic Ulcer / complications
  • Physicians, Family / psychology
  • Primary Health Care*
  • Proton Pump Inhibitors
  • Risk Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cardiotonic Agents
  • Cyclooxygenase 2 Inhibitors
  • Proton Pump Inhibitors
  • Aspirin